GW Pharma (GWPH) Posts Near-Breakeven Q4 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharma (GWPH) Bullish Stance Reiterated at Piper Jaffray Following Earnings, Conference and Dinner
December 4, 2014 7:14 AM ESTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and $147 price target on GW Pharma (NASDAQ: GWPH) following fireside chat with GWPH management (along with a dinner with management) at the 26th annual Piper Jaffray Healthcare Conference in New York yesterday. GWPH... More
